Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
InterveXion Therapeutics
company
About
InterveXion Therapeutics is a privately-held clinical-stage biopharmaceutical company
- 51 - 100
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $13.80M
- Industries
- Biopharma,Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2004
- Number Of Employee
- 51 - 100
- Operating Status
- Active
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Their lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866). They are also developing a novel vaccine (IXT-v100) against methamphetamine, which is in Preclinical Development.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
5
$52.80M
InterveXion Therapeutics has raised a total of
$52.80M
in funding over 2 rounds. Their latest funding was raised on
Nov 1, 2021 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 1, 2021 | Grant | $13.80M | 1 |
National Institutes of Health
|
— | Detail |
| Oct 5, 2020 | Grant | $8.10M | 1 | — | — | Detail |
| May 5, 2020 | Grant | $8.40M | 1 | — | — | Detail |
| Oct 10, 2017 | Grant | $8M | 1 | — | — | Detail |
| Jan 29, 2015 | Grant | $14.50M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
InterveXion Therapeutics is funded by 1 investors.
National Institutes of Health
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Institutes of Health
|
Yes | Grant |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
